SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies informs about press release

03 May 2023 Evaluate

Further to the intimation dated January 23, 2023, on the audit conducted by the United States Food and Drug Administration (USFDA) at its Solid Oral Formulation Facility (Plant 1) at Goa, from January 16, 2023 to January 20, 2023, Indoco Remedies has informed that the Company has received the Establishment Inspection Report (EIR) indicating closure of the inspection. It has enclosed press release in this regard.

The above information is a part of company’s filings submitted to BSE.

Indoco Remedies Share Price

228.20 -23.05 (-9.17%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×